Tauriga Sciences Inc. Appoints Dr. Lawrence A. May, M.D., F.A.C.P., to the Position of Chief Medical Officer Effective Immediately

Tauriga logo

LOS ANGELES, April 28, 2014 (GLOBE NEWSWIRE) -- Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified life sciences company with a pending acquisition in the cannabis space, is pleased to announce that Lawrence A. May, M.D., F.A.C.P., ("Dr. May") has accepted the position of Chief Medical Officer ("CMO"). Dr. May brings a unique combination of clinical, scientific and business experience that has been developed in his over thirty year career in private practice as well as in leadership roles in both public and private companies. Prior to becoming Chief Medical Officer, Dr. May has served on Tauriga's Medical Advisory Board and has been advising the Company on developing products in the natural medicine market.

Dr. May stated, "I am delighted to serve as Tauriga's Chief Medical Officer because I have always been interested in integrating the best of conventional medical practice with complementary modalities. I believe cannabis is a promising natural product that can possibly be quite beneficial with better forms, delivery systems and responsible physician supervision. I am enthusiastic about the potential to develop safer and more effective approaches to pain, anxiety, sleep and mood disorders. Collaborating with clinicians and scientists, I hope to improve the quality of life to an expanding population, particularly senior citizens."

Tauriga's CEO Dr. Stella M. Sung commented, "The appointment of Dr. May as Tauriga's Chief Medical Officer is significant to the Company for many reasons. His proven success in the specialty pharmaceutical and nutritional areas will be particularly valuable as Tauriga works to build its presence in the rapidly growing natural medicine market."

Personal BIO for Dr. Lawrence A. May, M.D., F.A.C.P., age 65

Dr. May earned his M.D. from Harvard Medical School ('74) and has practiced primary care internal medicine for over thirty years, developing one of the country's largest practices focused on integrating nutrition and the judicious use of supplements. While continuing to practice medicine, Dr. May has served on Boards of Directors, Scientific and Medical Advisory Boards and has lectured extensively nationally and internationally to professional and lay audiences.

In 1997 he was recruited to join The Medical and Scientific Advisory Board of Herbalife International where he ultimately served as Chairman and Executive Vice President for Medical and Scientific affairs. Dr. May has appeared as an expert on numerous television and radio shows and has consulted for law firms, pharmaceutical companies, early stage biotech and government, including the California Board of Medical Quality Assurance (BMQA). Dr. May has formulated many outstanding dietary supplements which are offered in physician offices and have been featured in highly successful infomercials.

Dr. May earned his undergraduate degree magna cum laude in Economics from Harvard University ('70) where he was elected to phi beta kappa.

About Tauriga Sciences, Inc.:

Tauriga Sciences, Inc. (TAUG) is a diversified life sciences company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space. The mission of the Company is to acquire and build a diversified portfolio of cutting edge technology assets that is capital efficient and of significant value to the shareholders. The Company's business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. On March 10, 2014, Tauriga signed a definitive agreement to acquire a California based topical cannabis cream company. Please visit the Company's corporate website at (www.tauriga.com).


This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Any securities offered or issued in connection with the above-referenced merger and/or investment have not been registered, and will be offered pursuant to an exemption from registration.


Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on TAUG's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which TAUG has little or no control. Such forward-looking statements are made only as of the date of this release, and TAUG assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by TAUG with the Securities and Exchange Commission. This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.

CONTACT: Tauriga Sciences, Inc.: Dr. Stella M. Sung Chairman and Chief Executive Officer Tauriga Sciences, Inc. www.tauriga.com San Diego: + 1-858-353-5749 Montreal: + 1-514-840-3697 Email: ssung@tauriga.com

Source:Tauriga Sciences Inc